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The Thrombolysis in Myocardial Infarction (TIMI) risk score (TRS) has proven value 
in predicting prognosis in unstable angina/non ST-elevation myocardial infarction 
(NSTEMI) as well as in ST-elevation myocardial infarction. The TRS system has little 
implication, however, in the extent of myocardial damage in high-risk patients with 
NSTEMI. A total of 1621 patients (63.6±12.2 years; 1043 males) with NSTEMI were 
enrolled in the Korea Acute Myocardial Infarction Registry (KAMIR). We analyzed the 
risk for major adverse cardiac events (MACE) during a 6-month follow-up period. The 
TRS system showed good correlation with MACE for patients in the low and inter-
mediate groups but had poor correlation when the high-risk group was included 
(p=0.128). The MACE rate was 3.8% for TRS 1, 9.4% for TRS 2, 10.7% for TRS 3, and 
12.3% for TRS 4 (HR=1.29, p=0.026). Among the biomarkers and clinical risk factors, 
elevated N-terminal pro-brain natriuretic peptide (NT-proBNP) (HR=2.61, p=0.001) 
and Killip class above III showed good correlation with MACE (HR=0.302, p＜0.001). 
Therefore, we revised an alternative clinical scoring system by including these two vari-
ables that reflect left ventricular dysfunction: age ＞  65 years, history of ischemic heart 
disease, Killip class above III, and elevated pro-BNP levels above the 75th percentile. 
This modified scoring system, when tested for validity, showed good predictive value 
for MACE (HR=1.64, p＜0.001). Compared with the traditional TRS, the novel alter-
native scoring system based on age, history of ischemic heart disease, Killip class, and 
NT-proBNP showed a better predictive value for 6-month MACE in high-risk patients 
with NSTEMI.
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　In patients with non-ST-elevation acute coronary syn-
drome (ACS), early risk stratification is of critical im-
portance, because the benefit of newer and more aggressive 
treatment strategies seems to be proportional to the risk 
of adverse clinical events.
1-3 Different scores capable of ear-
ly risk stratification have been developed on the basis of ini-
tial clinical history, electrocardiogram, and laboratory 
tests. Among others, the Thrombolysis in Myocardial 
Infarction (TIMI) risk score (TRS) is the most validated and 
the most extensively used in patients with non-ST-ele-
vation ACS.
4 However, this score does not utilize N-termi-
nal pro-brain natriuretic peptide (NT-proBNP) or Killip 21
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class from the candidate variables. The baseline measure 
of NT-proBNP has been identified as a powerful long-term 
determinant of cardiac events,
5-8 and Killip class at pre-
sentation has invariably been a component of previous 
scores,
9-12 emphasizing the importance of the clinical ex-
amination for signs of heart failure at the time of initial 
presentation.
　Accordingly, we hypothesized that incorporating NT- 
proBNP and Killip class into the TRS would enhance this 
score's ability to predict events. The aims of the present 
study were therefore to analyze the prognostic value of the 
TRS in patients with non-ST-elevation myocardial in-
farction (NSTEMI) and to construct, if possible, a new pre-
dictive model based on the TRS by including Killip class (≥
III) and NT-proBNP to increase prognostic efficacy for pa-
tients at high risk of adverse cardiac outcomes. 
　To this end, data from the Korea Acute Myocardial 
Infarction Registry (KAMIR), the largest multicenter reg-
istry in Korea of AMI to date, were utilized for score 
derivation. The KAMIR is a population-based, multicenter 
data collection registry evaluating treatment practice and 
outcomes that was launched in November 2005. The regis-
try includes 50 community and teaching hospitals that en-
roll more than 5000 patients annually. As of August 2007, 
the registry contained data on 12,634 patients. The KAMIR 
is supported by a research grant from the Korean Circula-
tion Society in commemoration of its 50
th Anniversary and 
aims to improve patient care by providing a greater under-
standing of patient management and outcomes in the rap-
idly evolving field of AMI treatment. 
MATERIALS AND METHODS
1. Patient population
　The study population consisted of 1261 consecutive pa-
tients with NSTEMI registered in the KAMIR database be-
tween January 2006 and December 2007. Patients of any 
age with NSTEMI were enrolled. The inclusion criteria 
were a history of chest pain at rest or other symptoms sug-
gestive of an acute coronary syndrome, with the most re-
cent episode occurring within 24 hours of admission. This 
could be associated with elevated levels of biomarkers of 
myocardial damage with or without ST or T wave changes 
on the electrocardiogram suggestive of myocardial ische-
mia. The biomarkers used were cardiac troponin I or T with 
a threshold for positivity of ≥99th percentile of the upper 
reference limit. After clinical evaluation, the patients un-
derwent determination of NT-proBNP at the emergency 
department (with at least one blood sample more than 6 
hours after the onset of pain).
2. TIMI risk score 
　The TRS was calculated from the initial clinical history, 
electrocardiogram, and laboratory values collected on 
admission. A retrospective calculation of the TRS was 
made for each patient. This yielded between 0 and 7 possi-
ble points according to the simple mathematical sum of 
each of the following characteristics: age of 65 years, ex-
istence of 3 or more classical risk factors (hypertension, hy-
percholesterolemia, diabetes mellitus, smoking, or family 
history of ischemic heart disease), previous significant cor-
onary artery disease (stenosis of ≥50%), aspirin con-
sumption in the previous 7 days, at least 2 episodes of angi-
na in the previous 24 hours, elevation of cardiac necrosis 
markers, and ST deviations of at least 0.5 mm.
4
3. Modified TIMI risk score 
　The Modified TIMI Risk Score (MTRS) was constructed 
to include markers of heart failure such as Killip class and 
NT-proBNP. This novel score was therefore made up of 4 
simpler variables, with a scoring system as follows: 
　1. One point if age is at least 65 years.
　2. One point if with a history of known coronary artery 
disease.
　3. One point if Killip class ≥III.
　4. One point if with elevation of NT-proBNP more than 
75 percentile points.
　The total score was still a simple mathematical sum but 
now ranged from 0 to 4. Based on the total risk score, pa-
tients were classified into risk categories of low risk (MTRS 
=0-1), intermediate risk (MTRS=2-3), and high risk 
(MTRS=4). 
4. Clinical follow-up
　Clinical follow-up was done 6 months after discharge by 
personal interview or telephone to record data relating to 
the control of risk factors, adherence to treatment, func-
tional class, and appearance of symptoms or complications. 
The incidence of the combined event of cardiovascular 
death, infarction, and need for revascularization was re-
corded during the follow-up period.
5. Study endpoints
　The study endpoint was the combination of major ad-
verse cardiac events (MACE), such as cardiac death, my-
ocardial infarction, recurrent ischemia, and bleeding, the 
last of which was defined according to the criteria of the 
TIMI trials.
13,14 This endpoint was analyzed both at 30 days 
and at 6 months.
6. Statistical analysis
　The log-rank test was performed for the Kaplan-Meier 
probability estimates. The relationship between NT- 
proBNP (either continuous or dichotomous) and the out-
come was adjusted for the effects of Killip classes and TRS 
(either continuous or dichotomous) with the use of stepwise 
multivariate logistic regression.
RESULTS
　The baseline clinical and laboratory characteristics of 
the MACE and no MACE groups are summarized in Table 
1. Patients with MACE were older and were more likely to 
have diabetes, a history of ischemic heart disease, a Killip 22
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Yes (n=220) No (n=1226)
Low (n=1003) 124 (12.4%) 876 (87.6%)
Intermediate (n=404)   87 (21.5%) 317 (78.5%) 0.128
High (n=39)     9 (23.1%)   30 (76.9%)
TIMI: Thrombolysis in Myocardial Infarction; MACE: major ad-
verse cardiac events.
TABLE 3. Six-month major adverse cardiac events according to 





Yes (n=220) No (n=1226)
0 (n=456) 34 (7.5%) 422 (92.5%)
1 (n=526)   54 (10.3%) 472 (89.7%)
2 (n=292)   64 (21.9%) 228 (78.1%) ＜0.001
3 (n=137)   49 (35.8%)   88 (64.2%)
4 (n=35)   19 (54.3%)   16 (45.7%)
TIMI: Thrombolysis in Myocardial Infarction; MACE: major ad-
verse cardiac events.




Yes (n=220) No (n=1226)
Gender (male %) 64.6 62.3 0.541
Age 69.0±12.2 63.4±12.2 ＜0.001
Diabetes mellitus   85 (38.6%) 386 (31.5%) 0.042
Hypertension 125 (56.8%) 626 (51.4%) 0.124
Smoking 118 (53.6%) 674 (55.2%) 0.660
Hyperlipidemia   22 (10.0%) 180 (14.7%) 0.072
Family History 21 (9.6%) 98 (8.0%) 0.425
Ischemic heart   69 (31.4%) 246 (20.1%) ＜0.001
 disease history
Killip class≥3   69 (31.4%) 133 (10.8%) ＜0.001
ST change   91 (41.7%) 417 (34.3%) 0.038
Shock 10 (4.5%) 12 (1.0%) 0.001
CHF   92 (51.7%) 401 (81.3%) ＜0.001
NT Pro-BNP (pg/ml)   8025.1±11072.8 2824.4±6777.4 ＜0.001
TnI (μg/l) 29.2±83.2 20.8±30.7 0.140
CRP (mg/l) 18.2±23.7   27.5±124.5 0.290
MACE: major adverse cardiac events; CHF: congestive heart fail-
ure; NT Pro-BNP: N-terminal pro-brain natriuretic peptide; TnI:
troponin I; CRP: C-reactive protein.
FIG. 2. Major adverse cardiac event (MACE)-free survival accord-
ing to the Modified TIMI Risk Score system.
FIG. 1. Major adverse cardiac event (MACE)-free survival accord-
ing to the TIMI Risk Score.
class ≥3, ST-segment change, cardiogenic shock, heart 
failure, and higher NT-ProBNP levels. Among the bio-
markers, elevated NT-proBNP levels above the 75th per-
centile had the best predictive value for MACE (HR=2.61, 
p=0.001) independently of other risk factors. Among the 
clinical risk factors, Killip class above III and the presence 
of heart failure or cardiogenic shock showed good correla-
tion with MACE (p＜0.001, p＜0.001, p=0.001, respec-
tively). The TRS system had good correlation with MACE 
for patients in the low and intermediate groups (Table 2, 
Fig. 1). The MTRS, which included Killip class ≥3 and 
NT-ProBNP levels, showed good predictive values for 
MACE (p＜0.001) (Table 3, Fig. 2). Also, the MTRS showed 
excellent discriminative properties among other risk fac-
tors and laboratory indices except for troponin-I and hs- 
CRP levels (Table 4). Multivariate analysis for predictions 
of MACE revealed NT-proBNP as the best prognostic in-
dicator (HR=0.394, p＜0.001) (Table 5). 
DISCUSSION
　The principal findings of the present study, in which a 23
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TABLE 5. Multivariate analysis for prediction of major adverse car-
diac events
HR 95% CI p value
Modified TIMI Score 0.562 0.333-0.950 ＜0.001
NT Pro-BNP 0.394 0.253-0.613 ＜0.001
Age ＞  65 0.746 0.513-1.084 0.345
Shock 0.486 0.153-1.539 0.220
Congestive heart failure 0.919 0.631-1.337 0.658
History of ischemic  0.644 0.428-0.970 0.035
 heart disease
TIMI: Thrombolysis in Myocardial Infarction; NT Pro-BNP: 
N-terminal pro-brain natriuretic peptide.




Male 79.2% 60.5% 56.2% 49.6% 51.4% ＜0.001
Age 52±8 66±10 72±9 74±7 75±5 ＜0.001
Diabetes mellitus 22.6% 31.6% 39.7% 50.4% 48.6% ＜0.001
Hypertension 42.5% 52.9% 56.5% 65.7% 68.6% ＜0.001
Smoking 68.9% 52.5% 47.1% 39.4% 38.2% ＜0.001
Dyslipidemia 15.6% 13.9% 10.7% 11.0% 34.3% ＜0.001
Family history 11.7% 8.2% 4.5% 5.1% 8.6% 0.001
History of ischemic heart disease 0% 36.4% 20.2% 9.4% 2.4% ＜0.001
Killip≥3 0% 2.7% 17.1% 75.2% 100.0% ＜0.001
ST change 28.4% 33.3% 39.2% 55.1% 50.0% ＜0.001
Shock 0.2% 0.6% 3.1% 5.8% 2.9% ＜0.001
CHF 19.2% 31.5% 51.9% 69.4% 96.7% ＜0.001
NT Pro-BNP (pg/ml) 518±596 1667±5301 6046±8476 13347±12909 14864±1108 ＜0.001
TnI (μg/l) 21.9±31.6 22.8±50.7 22.9±49.5 20.3±33.2   12.1±17.6 0.674
CRP (mg/l)   20.3±106.8   27.1±134.3   39.7±137.6 16.4±48.3     8.5±12.9 0.161
TIMI: Thrombolysis in Myocardial Infarction; CHF: congestive heart failure; NT Pro-BNP: N-terminal pro-brain natriuretic peptide;
TnI: troponin I; CRP: C-reactive protein.
powerful new cardiac risk score was created and validated, 
are as follows. First, in patients with acute NSTEMI, 
6-month cardiac events can be accurately predicted by us-
ing four clinical and laboratory variables readily available 
at the time of presentation. Second, baseline NT-proBNP 
and Killip class are powerful predictive variables of mortal-
ity and should be incorporated into risk models. Third, with 
the use of this prognostic score, three levels of risk strat-
ification can be created that identify patients with 
NSTEMI. Finally, the current risk score, when validated 
against the original TRS, provides more discriminatory ac-
curacy for 6-month clinical outcome, especially in a high- 
risk population. Accordingly, use of this alternative risk 
scoring system enables identification of patients with a 
poor long-term prognosis in whom close monitoring and in-
tensive therapy may be beneficial.
　Previous risk scoring systems have been proposed for esti-
mating in-hospital risk after admission for ACS,
4,10,16 in-
cluding risk models developed from large clinical trials or 
registry data by the TIMI clinical trials group.
4,10 All these 
scores were developed for short-term prognosis: events at 
14 days for the TRS and at 30 days for the PURSUIT risk 
score. However, a significant proportion of adverse events 
in patients with non-ST-elevation ACS occur after the first 
30 days, and it is not known whether these risk scores can 
also predict the development of MACE. On the other hand, 
it has been shown that an early invasive strategy has a 
prognostic benefit in long-term clinical follow-up.
17 
　The TRS is a scoring system with 7 risk variables in pa-
tients with unstable angina or NSTEMI.
4 This scale was 
created by retrospectively applying multivariate statistic 
models to the populations of two large clinical trials with 
heparins: TIMI 11B
2 and Efficacy and Safety of Subcuta-
neous Enoxaparin in Unstable Angina and Non-Q-wave 
Myocardial Infarction (ESSENCE).
18 It has since been vali-
dated in various studies such as CURE, PRISM-PLUS, and 
TACTICS-TIMI 18,
3,19 in which it has proved to be capable 
of predicting both the prognosis and the response to new 
therapies in both short- and long-term clinical follow-up. 
Nevertheless, there is little information on its applicability 
to daily clinical practice beyond the trials in which it was 
developed in selected populations.
13 Because of the low in-
cidence of signs of heart failure on admission in the pop-
ulation of the TIMI 11B trial used for the development of 
the TRS, variables such as Killip class or NT-proBNP were 
not included in the model. This is an important limitation, 
however, especially because the occurrence of heart failure 
is much more frequent in the real world than in selected 
patients from clinical trials, and its prognostic value is well 
established.
16,20,21 The GRACE score, which was based on 
a large registry of patients across the entire spectrum of 
acute coronary syndromes, shares many variables with 
previous mortality models.
22,23 However, heart failure at 
presentation, expressed as Killip class, constituted a great-24
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er proportion of the predictive information in this model 
than in previous clinical trial models. This may be partially 
explained by the fact that these patients were not excluded 
from the GRACE database. The other reason for the find-
ings presented above may come from the fact that in con-
trast with other well-established factors included in TRS, 
NT-proBNP has an advantage in detecting long-term con-
sequences of myocardial infarction such as left ventricular 
dysfunction or dilatation in addition to estimation of the 
amount of infarct size.
24 Previous studies demonstrated 
that NT-proBNP levels obtained in the first days after the 
onset of symptoms are predictive of short- and long-term 
mortality in patients with ACS.
6-8,25 Recently, Bazzino et 
al
26 and Grabowski et al
27 reported a highly significant ad-
ditive value of baseline NT-proBNP concentrations for 
6-month mortality assessed with common risk scales for 
non-ST-elevation ACS: TRS and the American College of 
Cardiology/American Heart Association classification. 
Our results are consistent with those of Bazzino's group, 
who showed that baseline NT-proBNP added prognostic 
information to risk scores for non-ST-elevation ACS.
26,27
　Systematic risk assessment for each patient provides de-
cisions regarding therapeutic interventions, triage to addi-
tional hospital care, and allocation of clinical resources. In 
this observational study, the MTRS was confirmed as an 
important long-term prognostic predictor in patients with 
NSTEMI; it establishes a risk curve ranging from a low to 
intermediate probability of cardiac events. Furthermore, 
we have obtained a new modified scale that, with the addi-
tion of presence of Killip class and NT-pro BNP to the other 
variables, increases prognostic capacity at no expense to 
the simplicity of the model. Our results also demonstrated 
that the long-term benefit of myocardial revascularization 
performed during initial hospital admission was only 
clearly observed in high-risk patients. These results agree 
with those of the FRISC II and TACTICS-TIMI 18 studies, 
which established the benefit of an early invasive strategy, 
but only for high-risk patients.
1,28,29 This, in part, could be 
explained by the constitution of the patient population in 
our study, most of whom already had a few risk factors of 
TRS at presentation, i.e., electrocardiogram changes and 
positive troponins. In this study, the diagnosis between un-
stable angina pectoris and acute myocardial infarction was 
usually made by the increased levels of serum troponins. 
Accordingly, the proportion of patients with intermediate 
to high-risk features may have been a lot higher compared 
with the patients included in the original TIMI 11B trial. 
　The present study confirms the capacity of the TRS for 
discriminating the probability of events in patients with 
NSTEMI. In fact, the 6-month MACE ranged from 12.4% 
for a score of 0 to 2 to 23.1% for high-risk patients (score 
of 5 or above). However, in our analysis, the prognostic val-
ue was less pronounced in high-risk patients, with 21.5% 
of events at 6 months for the intermediate TRS and 23.1% 
for the highest. The inclusion of Killip class and NT- 
proBNP as variables in the scale improved prognostic 
capacity. The excellent result of integrating these 2 varia-
bles may lie in the fact that they predict different compli-
cations. The TRS was developed to evaluate the risk of is-
chemic episodes (including myocardial infarction and the 
need for revascularization in the combined event), whereas 
the factors predicting mortality are usually related to left 
ventricular dysfunction (worse Killip class, NT-proBNP, 
etc). The MTRS may well be closer to real-world practice 
than previous studies limited to clinical trial populations 
or single-region registries. As such, we believe that clini-
cians will find greater confidence in its applicability in their 
practices. The KAMIR is the largest national registry study 
in Korea to include the entire spectrum of patients with 
AMI. It is designed to be representative of regional com-
munities and uses standardized criteria for defining AMI 
and hospital outcomes and quality control and audit 
measures. 
　In conclusion, the MTRS, 6-month post-discharge pre-
diction model, is a simple, robust tool for predicting death 
in patients with NSTEMI and has very good discriminative 
capacity. This risk assessment tool is likely to be clinically 
useful in the triage and management of patients eligible 
for early invasive therapy and may also serve as a valuable 
aid in clinical research for patients with NSTEMI. 
　A limitation of our study was the relatively small number 
of participants. Due to the low mortality rate in patients 
with TRS ＜4, incremental information offered by BNP 
measurement was practically limited to patients with high 
TRS. Another reason limiting the statistical analysis was 
the absence of ejection fraction in the multivariate model. 
However, our aim was to investigate the influence of Killip 
class and NT-proBNP on prognostic information obtained 
from clinical variables available on admission. Third, there 
may be unmeasured variables that would have provided 
further prognostic and longer-term information. The aim 
of this model, however, was to provide insight into factors 
associated with increased risk for 6-month clinical outcomes. 
The goal of achieving simplicity and ease of use must be bal-
anced against completeness and accuracy. Finally, it must 
be remembered that this was an observational, registry 
study, and the results should be extrapolated carefully to 
other environments with different populations and clinical 
management schemes. Further studies would be warran-
ted for verification of this new score system.
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